| Name | Title | Contact Details |
|---|
Vatech America is a Secaucus, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MJS BioLynx Inc. is a Brockville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ottobock was founded in Germany in 1919 by Otto Bock, a prosthetist. His vision of restoring mobility lives on today, growing to serve the world with more than 46 locations reaching more than 100 countries. The company is headquartered in Duderstadt, Germany, and has more than 5,000 employees. In the early 20th century, Otto Bock transformed the way prosthetic limbs were made. Instead of carving wood to fit a patient, he applied manufacturing techniques and created separate components (like knees and feet) that could be combined, altered or customized to create a limb that was still unique to each patient – but wasn’t built from scratch. Because of his pioneering work, Prosthetists were able to meet the demand generated by World War I and help veterans stay as active as possible. In 1958, our North American headquarters were established in Minneapolis, Minnesota. Our Canadian branch was founded in 1978 and is currently located in Toronto, Ontario. As the first branch, North America has led the way in advocating for and supporting local needs while still tapping into a global network of research and development, manufacturing, and clinical expertise. The people who use our products benefit from the synergy of a worldwide organization complemented by a local connection. Finally, Ottobock continues to give back to the community, supporting various charities and projects that are consistent with our mission of restoring independence.
Grapevine Executive Recruiters is a Outremont, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.